Last reviewed · How we verify

Altman Biomedical Consulting Pty. Ltd. — Portfolio Competitive Intelligence Brief

Altman Biomedical Consulting Pty. Ltd. pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Moov Head Lice Solution Moov Head Lice Solution marketed Pediculicide Dermatology / Parasitology
NeutraLice Lotion NeutraLice Lotion marketed Pediculicide Dermatology / Parasitology
NeutraLice Advance Solution NeutraLice Advance Solution marketed Pediculicide Dermatology / Parasitology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akorn, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Altman Biomedical Consulting Pty. Ltd.:

Cite this brief

Drug Landscape (2026). Altman Biomedical Consulting Pty. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/altman-biomedical-consulting-pty-ltd. Accessed 2026-05-17.

Related